EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The role and mechanism of esketamine in preventing and treating remifentanil-induced hyperalgesia based on the NMDA receptor–CaMKII pathway

Jiafang Wang, Yankun Feng, Zhong Qi, Jin Li, Zhijun Chen, Jinming Zhang, Degang Zhu

Open Life Sciences · 31.01.2024 · 19 (1)

DOI: 10.1515/biol-2022-0816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Life Sciences, online erschienen am 31.01.2024. Verfasst von Jiafang Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Wuhan No. 1 Hospital, No. 215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, 430022, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Remifentanil-induced hyperalgesia (RIH) is a common clinical phenomenon that limits the use of opioids in pain management. Esketamine, a non-competitive N -methyl- d -aspartate (NMDA) receptor antagonist, has been shown to prevent and treat RIH. However, the underlying effect mechanism of esketamine on RIH remains unclear. This study aimed to investigate the role and mechanism of esketamine in preventing and treating RIH based on the NMDA receptor–CaMKIIα pathway. In this study, an experimental animal model was used to determine the therapeutic effect of esketamine on pain elimination. Moreover, the mRNA transcription and protein expression levels of CaMKII and GluN2B were investigated to offer evidence of the protective capability of esketamine in ameliorating RIH. The results demonstrated that esketamine attenuated RIH by inhibiting CaMKII phosphorylation and downstream signaling pathways mediated by the NMDA receptor. Furthermore, ketamine reversed the upregulation of spinal CaMKII induced by remifentanil. These findings suggest that the NMDA receptor–CaMKII pathway plays a critical role in the development of RIH, and ketamine’s effect on this pathway may provide a new therapeutic approach for the prevention and treatment of RIH.

Schlagwörter

Stichwörter der Autor:innen

CaMKⅡGluN2Besketamineopioidspain managementremifentanil

Autor:innen und Institutionen

  • Department of Anesthesiology, Wuhan No. 1 Hospital, No. 215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, 430022, China.
  • Hubei Provincial Key Laboratory for Applied Toxicology, Hubei Center for Disease Control and Prevention, No. 35 Zhuodaoquan North Road, Hongshan District, Wuhan 430079, China.

Zitieren

APA

Wang, J., Feng, Y., Qi, Z., Li, J., Chen, Z., Zhang, J., & Zhu, D. (2024). The role and mechanism of esketamine in preventing and treating remifentanil-induced hyperalgesia based on the NMDA receptor–CaMKII pathway. Open Life Sciences, 19(1). https://doi.org/10.1515/biol-2022-0816

Vancouver

Wang J, Feng Y, Qi Z, Li J, Chen Z, Zhang J, et al. The role and mechanism of esketamine in preventing and treating remifentanil-induced hyperalgesia based on the NMDA receptor–CaMKII pathway. Open Life Sciences. 2024;19(1). doi:10.1515/biol-2022-0816

BibTeX
@article{Wang2024,
  author = {Wang, Jiafang and Feng, Yankun and Qi, Zhong and Li, Jin and Chen, Zhijun and Zhang, Jinming and Zhu, Degang},
  title = {The role and mechanism of esketamine in preventing and treating remifentanil-induced hyperalgesia based on the NMDA receptor–CaMKII pathway},
  journal = {Open Life Sciences},
  year = {2024},
  volume = {19},
  number = {1},
  doi = {10.1515/biol-2022-0816}
}
Kostenlos starten →